Overall Fundamental outlook

Business Operations:

Sector: Basic Materials
Industry: Specialty Chemicals

Jubilant Ingrevia Limited engages in the life science products and solutions in India, the United States, Europe, China and internationally. It operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health solutions. The Chemical intermediates segment offers acetyls and specialty ethanol. The company provides piperidines, metal complexes, choline salts, vitamin B3, Vitamin B4, picolinates, riboflavin phosphate sodium, nutritional premixes, antioxidants, straight ingredients, acetic anhydride, acetic acid, ethyl acetate, propionic anhydride, formaldehyde, bio acetic acid-food grade, acetaldehyde, and ethanol, as well as cyano, acetyl, amino, halo, alkyl, and aldehyde pyridines. In addition, it offers route design, process development, process optimization, and scale-up and commercial manufacturing of intermediates. Further, the company provides vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. It serves pharmaceutical, animal and human nutrition, agrochemical, personal and consumer care, and industrial customers. The company was formerly known as Jubilant LSI Limited and changed its name to Jubilant Ingrevia Limited in October 2020. Jubilant Ingrevia Limited was incorporated in 2019 and is headquartered in Noida, India.

Revenue projections:

Revenue projections for JUBLINGREA
Revenue projections for JUBLINGREA

Investors are expected to be cautious with Jubilant Ingrevia Limited, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 1.323000
forwardPE 26.802282
debtToEquity 26.094000
earningsGrowth 1.508000
revenueGrowth -0.022000
grossMargins 0.384620
operatingMargins 0.102070
trailingEps 15.870000
forwardEps 0.000000

JUBLINGREA's current ratio of 1.323 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, JUBLINGREA can comfortably cover its liabilities, reflecting a strong financial outlook.
JUBLINGREA's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
JUBLINGREA's low Debt-to-Equity ratio demonstrates that the company is not over-leveraged. This means it maintains a healthy balance between debt and equity, lowering financial risk and contributing to overall financial stability, which could attract risk-averse investors.

Price projections:

Price projections for JUBLINGREA
Price projections for JUBLINGREA

JUBLINGREA's price projections have consistently been revised higher, indicating growing confidence in the company's future potential. Analysts appear more optimistic about JUBLINGREA's ability to generate strong results going forward.

Recommendation changes over time:

Recommendations trend for JUBLINGREA
Recommendations trend for JUBLINGREA


Jubilant Ingrevia Limited has received a favorable buy bias from analysts recently, positioning it as a solid investment opportunity. This sentiment may attract more investors, who view Jubilant Ingrevia Limited as a stable option to park their money and potentially benefit from the company's continued growth and profitability.